Drugs / CART-38
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04351022 | Jul 2017 → Dec 2021 | acute myeloid leukemia | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-T-38 | “To investigate the clinical therapeutic efficacy and safety of CD38-targeted chimeric antigen receptor T (CAR-T-38) cells, we enrolled 6 AML patients who experienced relapse...” PMID 34034795 ↗ May 2021 |
| Action | Deplete | “FCM revealed that CAR-T-38 cells eliminated CD38 positive blasts without off-target effects on monocytes and lymphocytes.” PMID 34034795 ↗ May 2021 |
| Modality | Cell therapy | “targeted CD38 chimeric antigen receptor engineered T cell immunotherapy (CART)” NCT04351022 ↗ |
| Route | Intravenous | “Split intravenous infusion of CART-38 cells” NCT04351022 ↗ |